Not adjusted for splits or dividends. Gaps connect available observations.
Daily closing price data
Date
Close (USD)
Sep 21, 2026
$269.47
Sep 18, 2026
$269.99
Sep 17, 2026
$270.22
Sep 16, 2026
$267.28
Sep 16, 2026
$267.28
Sep 15, 2026
$267.20
Sep 15, 2026
$267.20
Sep 14, 2026
$266.32
Sep 14, 2026
$266.32
Sep 11, 2026
$265.58
Sep 11, 2026
$265.58
Sep 10, 2026
$266.35
Sep 10, 2026
$266.35
Sep 09, 2026
$267.08
Sep 09, 2026
$267.08
Sep 08, 2026
$269.12
Sep 08, 2026
$269.12
Sep 04, 2026
$275.23
Sep 03, 2026
$278.43
Sep 02, 2026
$275.21
Sep 02, 2026
$275.21
Sep 01, 2026
$271.19
Sep 01, 2026
$271.19
Aug 31, 2026
$265.85
Aug 31, 2026
$265.85
Aug 28, 2026
$268.04
Aug 28, 2026
$268.04
Aug 27, 2026
$265.77
Aug 27, 2026
$265.77
Aug 26, 2026
$270.00
Aug 26, 2026
$270.00
Aug 25, 2026
$273.14
Aug 25, 2026
$273.14
Aug 24, 2026
$273.04
Aug 24, 2026
$273.04
Aug 21, 2026
$270.24
Aug 21, 2026
$270.24
Aug 20, 2026
$267.37
Aug 20, 2026
$267.37
Aug 19, 2026
$273.41
Aug 19, 2026
$273.41
Aug 18, 2026
$271.11
Aug 18, 2026
$271.11
Aug 17, 2026
$262.37
Aug 17, 2026
$262.37
Aug 14, 2026
$260.35
Aug 14, 2026
$260.35
Aug 13, 2026
$262.08
Aug 12, 2026
$260.86
Aug 11, 2026
$259.80
Aug 10, 2026
$261.81
Aug 07, 2026
$259.24
Aug 06, 2026
$256.98
Aug 05, 2026
$257.59
Aug 05, 2026
$258.50
Aug 04, 2026
$254.93
Aug 04, 2026
$254.93
Aug 03, 2026
$254.41
Aug 03, 2026
$254.41
Jul 31, 2026
$256.35
Jul 31, 2026
$256.35
Jul 30, 2026
$255.82
Jul 30, 2026
$255.82
Jul 29, 2026
$265.53
Jul 29, 2026
$265.53
THE INVESTMENT STORY
What is driving the conversation?
AI synthesis
Sep 21, 2026, 20:38 UTC
Johnson & Johnson (JNJ) presents a classic defensive, defensive-growth investment narrative. Operating through its core Innovative Medicine and MedTech segments following the separation of its consumer health business, JNJ displays solid financial health with strong return on equity (35.0%), robust free cash flow generation ($22.2B TTM), and a low debt-to-equity ratio (0.61x). Analysts maintain a general 'Moderate Buy' consensus on the stock, pointing to solid FY2026 expected EPS around $11.60–$11.75 driven by broad portfolio strength. However, the stock is trading near multi-month highs around $270, placing its forward P/E ratio at ~21x–23x. This premium valuation compresses the forward dividend yield to ~2.0% (below its 5-year average of ~2.8%). Near-term head-winds include biosimilar competition for its blockbuster immunology drug Stelara and persistent talc litigation uncertainties. In summary, while core fundamental quality and price momentum above key moving averages support the equity narrative, stretched multiples suggest a balanced approach.
Generated market interpretation; verify claims and events against original reporting.
Questions to pressure-test the thesis
How do product durability, research spending and legal exposures affect the earnings assumptions?
What evidence would change the growth or margin assumptions?
Do earnings and free cash flow tell the same story?
FROM THESIS TO SETUP
Strategies worth investigating.
Portfolio fit unchecked
Current quotes or liquidity evidence are incomplete, so no strategy preview is published.
01 / VALUATION
What is priced in?
Market inputs Sep 21, 2026, 19:55 UTC
These ratios describe the saved financial and market inputs. A lower multiple alone does not establish that a stock is undervalued.
JNJ saved valuation metrics
Measure
Saved value
Trailing P/E
31.30x
Price / sales
6.63x
Price / book
7.97x
Price / free cash flowTrailing twelve months
29.21x
Free cash flow yieldTrailing twelve months
3.42%
EV / revenue
6.94x
Input dates, sources & methodology
Financial source
Recorded financial data
Financial inputs dated
Feb 11, 2026
Market inputs dated
Sep 21, 2026, 19:55 UTC
Model evidence coverage
70.0% Input coverage, not probability of success
Valuation model / version
general · V1.4
Ratios are Fidusor calculations or saved provider inputs. The market-data provider is not separately identified in this snapshot. Only available measures are shown; this is not a complete valuation or a fair-value target.
02 / WHAT CHANGED
Follow the evidence over time.
Compared with the saved observation from Sep 21, 2026, 16:00 UTC. These are changes in recorded ratios, not explanations of a price move.
Price / sales6.68x → 6.63x
Price / book8.03x → 7.97x
Price / free cash flow29.43x → 29.21x
Free cash flow yield3.40% → 3.42%
EV / revenue6.99x → 6.94x
03 / FILING ACTIVITY
Read what was actually reported.
Recent source-linked records in Fidusor's tracked universe. Disclosures describe earlier activity and may not reflect current holdings or intent.
Insider disclosures
Insider filings may include purchases, sales, grants and exercises. Read the transaction details before drawing a conclusion.
No qualifying source-linked records are available in the recent saved coverage. This does not mean no activity occurred.
Reported institutional position changes
13F changes compare quarter-end positions. The period shown is not a trade execution date. Reports omit short positions and do not establish real-time buying.
Fidusor